References
- Ostrosky-Zeichner L, Rex JH, Bennett J, et al. Deeply invasive candidiasis. Infect Dis Clin North Am 2002;16:821-35
- Playford EG, Sorrell TC. Optimizing therapy for Candida infections. Semin Respir Crit Care Med 2007;28:678-88
- Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007;27:369-88
- Vehreschild JJ, Cornely OA. Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice. Future Microbiol 2006;1:161-70
- Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45:883-93
- Cornely OA, Sidhu M, Odeyemi I, et al. Economic analysis of micafungin versus liposomal amphotericin b for treatment of candidaemia and invasive candidiasis in Germany. Curr Med Res Opin 2008;24:1743-53
- Drummond MF, O’Brien B, Stoddard GL, et al. Methods for the Evaluation of Health Care Programmes. Oxford Medical Publications: Oxford University Press, 1999
- Goeree R, Burke N, O’Reilly D, et al. Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Curr Med Res Opin 2007;23:671-82
- British Medical Association. British National Formulary 54: BMJ Publishing Group Ltd and RPS Publishing, September 2007
- Newcastle Upon Tyne Trust Tariffs: 2006/2007
- Boland A, Haycox A, Bagust A, et al. A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses. Health Technology Assessment 2003;7(36):47
- Schwengel DA, McGready J, Berenholtz SM, et al. Peripherally inserted central catheters: a randomized, controlled, prospective trial in pediatric surgical patients. Anesth Analg 2004;99:1038-43
- Iselin L, Naef M, Wagner HE, et al. Peripheral access for implantable venous access device. EJVES 2005; Extra 10:54-6
- OANDA.com, the currency site, 2007. Available at: http://www.oanda.com/convert/fxhistory
- Curtis L, Netten A. Unit Costs of Health and Social Care 2005. Personal Social Services Research Unit: The University of Kent, 2005
- Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997;98:711-18
- Eiland EH, Hassoun A, English T. Points of concern to the micafungin versus caspofungin trial. Clin Infect Dis 2008;46:640-1; author reply 641
- Bruynesteyn K, Gant V, McKenzie C, et al. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. Eur J Haematol 2007;78:532-9
- Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391-402